Cooling after cardiac arrest yields no extra benefit

Published on 16/11/2026 • By Maisie Pearson • Risk Factors
Cooling after cardiac arrest yields no extra benefit - cooling after
A secondary analysis of the Target Temperature Management (TTM) and TTM2 trials was published in Critical Care.

Temperature management is a critical component of post-resuscitation care after out-of-hospital cardiac arrest (OHCA). Researchers have examined whether the benefits of cooling differ according to early neurological findings and clinical signs of cerebral ischaemic burden.

A secondary analysis of the Target Temperature Management (TTM) and TTM2 trials was published in Critical Care. The work evaluated the impact of cooling on 2,789 adults who suffered OHCA. The median age of participants was 65 years, and 79.9% were men.

Study Methodology

The team applied advanced machine-learning techniques to test whether individual patient characteristics could reveal subgroups more likely to benefit from a target temperature of 33°C.

Patients had been randomised to receive therapeutic hypothermia at a target of 33 °C, while the comparator arm maintained controlled normothermia with core temperatures kept between 36.0 °C and 37.7 °C.

The primary endpoint was all-cause mortality at six months, while the secondary outcome was poor functional recovery, defined as a modified Rankin Scale score of 4–6.

Investigators explored whether treatment effects shifted according to factors linked to the length and intensity of cerebral ischaemia, pre-hospital circumstances, and neurological examination results at hospital admission. They used causal forests and Bayesian additive regression trees (BART) to map variation in treatment response.

Results

At the six-month mark, mortality reached 49.4% among patients who received cooling to 33°C and 47.9% among those who were managed with controlled normothermia. The analysis uncovered only minimal variation in estimated individual treatment effects, and no statistically significant evidence indicated that baseline neurological findings or clinical markers of ischaemic burden altered the impact of the low-temperature protocol.

In the pooled analysis, the estimated conditional mean mortality risk differences spanned from –1.2% to 2.1% when using causal-forest models, and from –0.5% to 1.5% with Bayesian additive regression trees.

The findings were consistent when poor functional outcome at six months was examined. None of the methods identified a clinically meaningful pattern suggesting that patients with particular neurological characteristics or indicators of prolonged ischaemia experienced substantially better outcomes with hypothermia.

Bayesian posterior probabilities that hypothermia conferred a survival benefit ranged only between 42% and 53%, showing the absence of a convincing subgroup-specific advantage.

Implications

The findings question the long-standing assumption that more severe initial neurological injury automatically translates into a greater chance of benefit from deeper cooling. Although the biological rationale for temperature reduction stays plausible, the study indicates that routinely available indicators of ischaemic load and early neurological status are insufficient to single out patients who would respond preferentially to a 33°C target.

These findings emerged from a combined assessment of both TTM and TTM2 trial populations, providing a pooled perspective that strengthens the inference that routinely available clinical markers do not modify the effect of temperature lowering.

For intensivists, the data reinforce the need to separate the overall effectiveness of temperature management from the idea that selected individuals might derive extra advantage. While targeted temperature management continues to be relevant in clinical practice, the available markers of neurological injury and ischaemic burden did not pinpoint a group with improved survival or functional outcomes when the cooling protocol was applied.

The investigators examined the variables available in the original trials, and these may not fully capture the biological complexity of hypoxic-ischaemic brain injury. More detailed neurological biomarkers, neuroimaging findings or physiological measurements might identify treatment-responsive subgroups that were not detectable in this analysis.

In everyday practice, clinicians should therefore exercise caution when contemplating personalized temperature-control strategies based solely on a patient’s neurological severity. Instead, they are advised to rely on established trial evidence, conduct thorough individual clinical assessments, and prioritize the avoidance of fever.

You may also like

Leave a Comment

Your email address will not be published. Required fields are marked *